Loading…
Loading…
PTCHF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PTCHF and 80,000+ other tickers.
See exactly how PTCHF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PTCHF and 80,000+ other tickers.
PureTech Health plc operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts in the United States on the discovery, advancement, and market introduction of novel therapeutic solutions. The company's diverse pipeline targets a wide array of challenging medical conditions, including inflammatory, fibrotic, and immunological disorders, intractable cancers, various lymphatic and gastrointestinal issues, as well as neurological and neuropsychological ailments. Among its significant offerings, PureTech provides KarXT, a treatment designed to modulate muscarinic…
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial...
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9 million. In London, PureTech shareholders saw the share price climb 9.56% to 139.8p.
PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript
PureTech Health plc (OTCMKTS:PTCHF - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 56,594 shares, an increase of 69.4% from the January 15th total of 33,408 shares. Based on an average daily trading volume, of 144,900